v3.26.1
CONCENTRATION
 9 Months Ended
Mar. 31, 2026
Risks and Uncertainties [Abstract]  
CONCENTRATION

NOTE 14 – CONCENTRATION

 

Business segments

 

The Company's operations are just organized into one business segment based on the nature of products and services offered. Summary operating results for each of its products were as follows:

 

   Three months Ended
March 31,		   Nine months Ended
March 31,		 
   2026   2025   2026   2025 
Sales            
Anti-Aging & Immune Support  $14,010   $50,008   $184,764   $254,404 
Targeted System Support   9,655    6,140    55,286    32,809 
Herbal Insulin Support   2,478    -    18,752    - 
Total sales  $26,143   $56,148   $258,802   $287,213 
Cost of Goods Sold                    
Anti-Aging & Immune Support  $1,226   $5,858   $64,286   $22,505 
Targeted System Support   1,392    473    16,118    3,003 
Herbal Insulin Support   992    -    6,650    - 
Total cost of goods sold  $3,610   $6,331   $87,054   $25,508 
Gross Profit                    
Anti-Aging & Immune Support  $12,784   $44,150   $120,478   $231,899 
Targeted System Support   8,263    5,667    39,168    29,806 
Herbal Insulin Support   1,486    -    12,102    - 
Total gross profit  $22,533   $49,817   $171,748   $261,705 
Selling Expense                    
Anti-Aging & Immune Support  $628   $13,363   $17,600   $33,855 
Targeted System Support   3,068    892    15,206    3,594 
Herbal Insulin Support   2,190    -    25,406    - 
Total selling expense  $5,886   $14,255   $58,212   $37,449 

 

Major customers

 

For the three months ended March 31, 2026, three major customers accounted for approximately 13%, 10% and 10% respectively of our total revenue during the period. For the three months ended March 31, 2026, six major customers accounted for approximately 19% to 10% of our total revenue during the period. There was no concentration in accounts receivable for the three months ended March 31, 2026 and 2025.

 

For the nine months ended March 31, 2026, two major customers accounted for approximately 22% each of our total revenue during the period. For the nine months ended March 31, 2025, only one major customer accounted for approximately 11% of our total revenue during the period. There was no concentration in accounts receivable for the nine months ended March 31, 2026 and 2025.

 

   For the three months ended March 31,   For the nine months ended March 31, 
   2026   2025   2026   2025 
   Amounts   Percentages   Amounts   Percentages   Amounts   Percentages   Amounts   Percentages 
Customer A  $3,406    13%  $10,560    19%  $57,000    22%  $32,980    11%
Customer B   2,613    10%   6,900    12%   55,877    22%   -    -%
Customer C   2,600    10%   6,708    12%   -    -%   -    -%
Customer D   -    -%   6,012    11%   -    -%   -    -%
Customer E   -    -%   6,000    11%   -    -%   -    -%
Customer F  $-    -%  $5,580    10%  $-    -%  $-    -%

 

Major suppliers

 

For the three months ended March 31, 2026 and 2025, the Company has one supplier representing 100% of the total purchases during each period. There was no concentration in account payable for the three months ended March 31, 2026 and 2025.

 

For the nine months ended March 31, 2026, the Company had two suppliers representing approximately 53% and 43%, respectively of the total purchases during the period. For the nine months ended March 31, 2025, the Company had three suppliers representing approximately 63%, 25% and 12%, respectively of the total purchases during the period. There was no concentration in account payable for the nine months ended March 31, 2026 and 2025.

 

   For the three months ended March 31,   For the nine months ended March 31, 
   2026   2025   2026   2025 
   Amounts   Percentages   Amounts   Percentages   Amounts   Percentages   Amounts   Percentages 
Supplier A  $5,211    100%  $5,138    100%  $38,920    53%  $41,668    63%
Supplier B   -    -    -    -    31,668    43%   17,019    25%
Supplier C  $-    - %  $-    - %  $-    -%  $7,940    12%